Risperidone versus olanzapine for schizophrenia

The Cochrane Database of Systematic Reviews
M B JayaramS Stroup

Abstract

Antipsychotic medication is a mainstay of treatment for schizophrenia. Risperidone and olanzapine are popular choices among the new generation drugs. To determine the clinical effects, safety and cost effectiveness of risperidone compared with olanzapine for treating schizophrenia. We searched the Cochrane Schizophrenia Group's Register (Sept 2005) which is based on regular searches of, amongst others, BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO. References of all identified studies were inspected for further trials. We also contacted relevant pharmaceutical companies for additional information. We included all clinical randomised trials comparing risperidone with olanzapine for schizophrenia and schizophrenia-like psychoses. We extracted data independently. For homogenous dichotomous data we calculated random effects, relative risk (RR), 95% confidence intervals (CI) and, where appropriate, numbers needed to treat/harm (NNT/H) on an intention-to-treat basis. For continuous data, we calculated weighted mean differences (WMD). We found no difference for the outcome of unchanged or worse in the short term (n=548, 2 RCTs, RR 1.00 CI 0.88 to 1.15). One study favoured olanzapine for the outcome of relapse/rehospitalisation...Continue Reading

References

Nov 1, 1992·Journal of General Internal Medicine·G W DivineL M Frazier
Jan 1, 1992·Psychological Medicine. Monograph Supplement·A JablenskyA Bertelsen
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jul 1, 1982·Archives of General Psychiatry·N C Andreasen
Mar 10, 1994·The New England Journal of Medicine·W T Carpenter, R W Buchanan
Mar 1, 1993·General Hospital Psychiatry·D R Lipsitt
Feb 1, 1996·Controlled Clinical Trials·A R JadadH J McQuay
Nov 9, 1996·BMJ : British Medical Journal·D G Altman, J M Bland
May 1, 1997·Journal of Clinical Pharmacology·P F Buckley
Sep 26, 1997·BMJ : British Medical Journal·J M Bland, S M Kerry
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Jul 11, 1998·The American Journal of Psychiatry·R R ConleyS Zaremba
Nov 26, 1998·The British Journal of Psychiatry : the Journal of Mental Science·C KellyS Carey
Jun 1, 1999·Clinical Neurology and Neurosurgery·J KalitaU K Misra
Feb 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·M MarshallM Fenton
May 5, 2000·The Cochrane Database of Systematic Reviews·E KennedyS Gilbody
May 5, 2000·The Cochrane Database of Systematic Reviews·A BagnallJ Kleijnen
Oct 18, 2000·The Cochrane Database of Systematic Reviews·A BagnallM L Leitner
Dec 6, 2000·The Journal of Clinical Psychiatry·B J KinonV L Stauffer
Apr 20, 2001·JAMA : the Journal of the American Medical Association·D MoherUNKNOWN CONSORT Group (Consolidated Standards of Reporting Trials)
Jul 4, 2001·Psychopharmacology·K WahlbeckS Leucht
Jul 7, 2001·BMJ : British Medical Journal·P JüniM Egger
Oct 31, 2001·Psychiatric Services : a Journal of the American Psychiatric Association·L CitromeJ A Lieberman
Jan 5, 2002·The American Journal of Psychiatry·Peter TurroneAlastair J Flint
Mar 1, 2002·The American Journal of Psychiatry·Uriel Heresco-LevyDaniel C Javitt
Jun 22, 2002·The Cochrane Database of Systematic Reviews·N E MotaB G Soares
Sep 27, 2002·Statistics in Medicine·Allan Donner, Neil Klar
Dec 11, 2002·Journal of Clinical Pharmacy and Therapeutics·X S RenD R Miller
Dec 24, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Daniel E CaseyKenneth W Sommerville
Feb 4, 2003·The American Journal of Psychiatry·Jean-Pierre LindenmayerJeffrey A Lieberman
Mar 28, 2003·Wiener klinische Wochenschrift·Blanka Kores PlesnicarIvan Krajnc

❮ Previous
Next ❯

Citations

Oct 9, 2007·Schizophrenia Bulletin·Mahesh B JayaramThomas S Stroup
Jun 11, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Andrew P YuGlenn Philips
Nov 2, 2016·The Cochrane Database of Systematic Reviews·Arka ChattopadhyayGhiselle Green
Jan 21, 2011·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Dec 10, 2014·International Journal of Methods in Psychiatric Research·Fenneke M van HasseltAnton J M Loonen
Apr 22, 2008·The Cochrane Database of Systematic Reviews·A Nussbaum, T S Stroup
Mar 20, 2010·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Nov 11, 2011·Journal of Psychiatric and Mental Health Nursing·M A Aldridge
Nov 9, 2019·Journal of Medical Internet Research·Jill S BorchertKirk E Dineley
Oct 8, 2009·The Oncologist·Shirley H Bush, Eduardo Bruera
Apr 15, 2016·The Cochrane Database of Systematic Reviews·Stephanie SampsonJohn M Davis
Jul 3, 2009·Pharmacoepidemiology and Drug Safety·Hélène PeyrièreUNKNOWN French Network of the Pharmacovigilance Centers
Aug 12, 2009·Revista de saúde pública·Leandro Mendonça LindnerGeder Evandro Motta Grohs
Apr 19, 2011·Sleep Medicine Clinics·Andrew D Krystal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here